Univariate Cox proportional hazards regression modeling time from enrollment to SPMs
| Variable . | n/N (%) . | Time to SPMs from enrollment . | |
|---|---|---|---|
| HR (95% CI) . | P* . | ||
| Female sex | 451/1148 (39%) | 0.77 (0.47-1.25) | .288 |
| White race | 1008/1148 (88%) | 2.65 (0.97-7.25) | .058 |
| Age ≥ 65 y | 266/1148 (23%) | 2.06 (1.25-3.39) | .004 |
| IgA isotype | 270/1143 (24%) | 0.83 (0.46-1.48) | .524 |
| IgG isotype | 624/1143 (55%) | 0.85 (0.54-1.34) | .487 |
| Albumin < 3.5 g/dL | 275/1143 (24%) | 0.66 (0.33-1.33) | .249 |
| B2M ≥ 3.5 mg/L | 478/1145 (42%) | 1.03 (0.64-1.68) | .895 |
| B2M > 5.5 mg/L | 238/1145 (21%) | 1.43 (0.80-2.56) | .233 |
| IPSS Stage I | 565/1141 (50%) | 1.24 (0.76-2.00) | .392 |
| IPSS Stage II | 339/1141 (30%) | 0.60 (0.33-1.10) | .098 |
| IPSS Stage III | 238/1145 (21%) | 1.43 (0.80-2.56) | .233 |
| CRP ≥ 8 mg/L | 423/1136 (37%) | 0.85 (0.51-1.39) | .512 |
| Creatinine ≥ 2.0 mg/dL | 96/1133 (8%) | 1.81 (0.87-3.79) | .113 |
| Hb < 10 g/dL | 312/1146 (27%) | 0.90 (0.52-1.57) | .716 |
| LDH ≥ 190 U/L | 328/1145 (29%) | 1.30 (0.78-2.16) | .309 |
| Platelet count < 150 × 109/L | 171/1146 (15%) | 0.53 (0.22-1.33) | .177 |
| Cytogenetic abnormalities | 367/1136 (32%) | 1.64 (1.01-2.66) | .045 |
| GEP70 high-risk | 123/792 (16%) | 0.71 (0.22-2.30) | .571 |
| GEP80 high-risk | 56/792 (7%) | 0.68 (0.09-4.92) | .701 |
| K/L FLC ratio | N = 478 | 1.00 (1.00-1.00) | .515 |
| Kappa FLC | N = 614 | 1.00 (1.00-1.00) | .464 |
| Kappa FLC > 168 | 70/614 (11%) | 1.23 (0.43-3.51) | .697 |
| Lambda FLC | N = 615 | 1.00 (1.00-1.00) | .456 |
| Thalidomide | 803/1148 (70%) | 1.16 (0.71-1.89) | .561 |
| Variable . | n/N (%) . | Time to SPMs from enrollment . | |
|---|---|---|---|
| HR (95% CI) . | P* . | ||
| Female sex | 451/1148 (39%) | 0.77 (0.47-1.25) | .288 |
| White race | 1008/1148 (88%) | 2.65 (0.97-7.25) | .058 |
| Age ≥ 65 y | 266/1148 (23%) | 2.06 (1.25-3.39) | .004 |
| IgA isotype | 270/1143 (24%) | 0.83 (0.46-1.48) | .524 |
| IgG isotype | 624/1143 (55%) | 0.85 (0.54-1.34) | .487 |
| Albumin < 3.5 g/dL | 275/1143 (24%) | 0.66 (0.33-1.33) | .249 |
| B2M ≥ 3.5 mg/L | 478/1145 (42%) | 1.03 (0.64-1.68) | .895 |
| B2M > 5.5 mg/L | 238/1145 (21%) | 1.43 (0.80-2.56) | .233 |
| IPSS Stage I | 565/1141 (50%) | 1.24 (0.76-2.00) | .392 |
| IPSS Stage II | 339/1141 (30%) | 0.60 (0.33-1.10) | .098 |
| IPSS Stage III | 238/1145 (21%) | 1.43 (0.80-2.56) | .233 |
| CRP ≥ 8 mg/L | 423/1136 (37%) | 0.85 (0.51-1.39) | .512 |
| Creatinine ≥ 2.0 mg/dL | 96/1133 (8%) | 1.81 (0.87-3.79) | .113 |
| Hb < 10 g/dL | 312/1146 (27%) | 0.90 (0.52-1.57) | .716 |
| LDH ≥ 190 U/L | 328/1145 (29%) | 1.30 (0.78-2.16) | .309 |
| Platelet count < 150 × 109/L | 171/1146 (15%) | 0.53 (0.22-1.33) | .177 |
| Cytogenetic abnormalities | 367/1136 (32%) | 1.64 (1.01-2.66) | .045 |
| GEP70 high-risk | 123/792 (16%) | 0.71 (0.22-2.30) | .571 |
| GEP80 high-risk | 56/792 (7%) | 0.68 (0.09-4.92) | .701 |
| K/L FLC ratio | N = 478 | 1.00 (1.00-1.00) | .515 |
| Kappa FLC | N = 614 | 1.00 (1.00-1.00) | .464 |
| Kappa FLC > 168 | 70/614 (11%) | 1.23 (0.43-3.51) | .697 |
| Lambda FLC | N = 615 | 1.00 (1.00-1.00) | .456 |
| Thalidomide | 803/1148 (70%) | 1.16 (0.71-1.89) | .561 |
HR indicates hazard ratio; 95% CI, 95% confidence interval; B2M, β-2-microglobulin; IPSS, International Prognostic Scoring System; CRP, C-reactive protein; Hb, hemoglobin; LDH, lactate dehydrogenase; GEP, gene-expression profiling; and FLC, free light chain.
P value from Wald χ2 test in cox regression. All univariate P values are reported regardless of significance. The multivariate model uses stepwise selection with an entry level of P = .1 and the variable remains if it meets the P = .05 level. A multivariate P value > .05 indicates a variable forced into the model with significant variables chosen using stepwise selection.